Tumor educated platelets, a promising source for early detection of hepatocellular carcinoma: Liquid biopsy an alternative approach to tissue biopsy

被引:24
|
作者
Asghar, Sidra [1 ]
Waqar, Walifa [1 ]
Umar, Muhammad [2 ]
Manzoor, Sobia [1 ]
机构
[1] Natl Univ Sci & Technol, Atta Ur Rahman Sch Appl Biosci, H12, Islamabad 44000, Pakistan
[2] Holy Family Hosp, Ctr Liver & Digest Dis, Rawalpindi, Pakistan
关键词
HCC; Platelets; Tumor educated platelets (TEP); Liquid biopsy; TGF-BETA; CANCER; RNA; BLOOD; EPIGENETICS; RESISTANCE; EVOLUTION; PATHWAY;
D O I
10.1016/j.clinre.2020.03.023
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose: Liver cancer is considered to be the sixth deadliest cancer worldwide. Hepatocellular carcinoma (HCC) is known to be the most prevalent type of liver cancer. The number of deaths due to HCC reported per year is on a constant rise especially in lesser developed countries. There are several contributing factors to this rise in number. Among other contributing factors is the late diagnosis of HCC. Patients are usually diagnosed when the disease reaches its advance stage. The present study was conducted with total 30 samples. It was designed for investigating the potential of TGF-beta, NF-kappa beta, VEGF, AKT and PI3K as RNA based biomarkers in tumor educated platelets for early detection of HCC. Results: The results obtained from the transcriptional analysis revealed a significant high expression of TGF-beta, NF-kappa beta, VEGF by 2.48, 2.35 and 2.78 folds respectively in comparison to the control. On the other hand, a decrease in expression by 0.6 and 0.65 folds was observed in AKT and PI3K respectively in comparison to controls. Although all selected RNA biomarkers showed promising potential to detect HCC however, AKT and PI3K were better able to detect early stage HCC. Conclusions: The results obtained clearly indicate the increased expression of TGF-beta, NF-kappa beta, VEGF in HCC patients. All these biomarkers are previously known for cancer initiation, progression and metastasis. The significant decrease in expression of AKT and PI3K in HCC patients needs further investigation. All the selected RNA biomarkers can be used for detection of HCC as they were able to distinguish HCC patients from controls successfully with AKT and PI3K showing better potential to detect early stage HCC. However, translational analysis for all these RNA biomarkers should be performed to gain further evidence for the ability of these biomarkers to be used for early HCC detection. (C) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:836 / 844
页数:9
相关论文
共 47 条
  • [11] Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
    Ye, Qianwei
    Ling, Sunbin
    Zheng, Shusen
    Xu, Xiao
    MOLECULAR CANCER, 2019, 18 (1)
  • [12] DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection
    Markou, A.
    Londra, D.
    Tserpeli, V
    Kollias, I
    Tsaroucha, E.
    Vamvakaris, I
    Potaris, K.
    Pateras, I
    Kotsakis, A.
    Georgoulias, V
    Lianidou, E.
    CLINICAL EPIGENETICS, 2022, 14 (01)
  • [13] Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?
    Ogle, Laura F.
    Orr, James G.
    Willoughby, Catherine E.
    Hutton, Claire
    McPherson, Stuart
    Plummer, Ruth
    Boddy, Alan V.
    Curtin, Nicola J.
    Jamieson, David
    Reeves, Helen L.
    JOURNAL OF HEPATOLOGY, 2016, 65 (02) : 305 - 313
  • [14] Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma
    Hu, Shiqi
    Liu, Yaqin
    Yang, Qidong
    Chen, Lin
    Chai, Huizi
    Xiao, Mingzhe
    Qi, Chuang
    Qiu, Wei
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 532 - 538
  • [15] Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma
    Temraz, Sally
    Nasr, Rihab
    Mukherji, Deborah
    Kreidieh, Firas
    Shamseddine, Ali
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2022, 22 (05) : 507 - 518
  • [16] Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma
    Wu, Xiaolin
    Li, Jiahui
    Gassa, Asmae
    Buchner, Denise
    Alakus, Hakan
    Dong, Qiongzhu
    Ren, Ning
    Liu, Ming
    Odenthal, Margarete
    Stippel, Dirk
    Bruns, Christiane
    Zhao, Yue
    Wahba, Roger
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2020, 16 (09): : 1551 - 1562
  • [17] Application of Data Science in Circulating Tumor DNA Detection: A Promising Avenue Towards Liquid Biopsy
    Li, Ming
    Xie, Sisi
    Lu, Chenyu
    Zhu, Lingyun
    Zhu, Lvyun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [18] Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy
    Qu, Chunfeng
    Wang, Yuting
    Wang, Pei
    Chen, Kun
    Wang, Minjie
    Zeng, Hongmei
    Lu, Jianquan
    Song, Qianqian
    Diplas, Bill H.
    Tan, Da
    Fan, Chunsun
    Guo, Qigao
    Zhu, Zheng
    Yin, Huihui
    Jiang, Liping
    Chen, Xixi
    Zhao, Hui
    He, Huan
    Wang, Yong
    Li, Guangyu
    Bi, Xinyu
    Zhao, Xinming
    Chen, Taoyang
    Tang, Hongping
    Lv, Chuanguo
    Wang, Dongmei
    Chen, Wanqing
    Zhou, Jianguo
    Zhao, Hong
    Cai, Jianqiang
    Wang, Xiaoyue
    Wang, Sizhen
    Yan, Hai
    Zeng, Yi-Xin
    Cavenee, Webster K.
    Jiao, Yuchen
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (13) : 6308 - 6312
  • [19] Tumor-Educated Platelets as a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma
    Xiao, Ruotao
    Liu, Cheng
    Zhang, Bo
    Ma, Lulin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [20] DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection
    Α. Markou
    D. Londra
    V. Tserpeli
    Ι. Kollias
    E. Tsaroucha
    I. Vamvakaris
    K. Potaris
    I. Pateras
    Α. Kotsakis
    V. Georgoulias
    Ε. Lianidou
    Clinical Epigenetics, 2022, 14